Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143480 · ClinicalTrials.gov registry record
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
A clinical trial of Cancer and Asthma, sponsored by National Institute of Environmental Health Sciences (NIEHS).
- Recruiting
- Registry status
- 725
- Enrollment target
- 1
- Study location
NCT01143480: Recruiting study of Cancer and Asthma, sponsored by National Institute of Environmental Health Sciences (NIEHS).
NCT01143480 is a study of Cancer and Asthma that is actively recruiting participants, run by National Institute of Environmental Health Sciences (NIEHS). The registered enrollment target is 725 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01143480, a study of Cancer and Asthma, is actively recruiting participants, sponsored by National Institute of Environmental Health Sciences (NIEHS).
- RECRUITING
- Registry status
- 725 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s response can contribute to chronic illnesses or diseases such as asthma and certain types of cancers. Objectives: \- To examine how specific genes and proteins in blood cells respond to environmental exposures. Eligibility: \- Healthy volunteers between 18 and 45 years of age. Design: * The study will involve one visit of 45 to 60 minutes. * Participants will be screened with a brief physical examination and finger stick to determine if they are eligible to donate blood for the study, and will complete a questionnaire about any medications or other drugs (e.g., cigarettes) they may be taking. * Participants will provide a blood sample for research purposes.
Primary Outcome
The primary endpoints of this study are for both cell types and will be levels of 6 cytokines \[TNF alpha, IL-6, MIP-2, IL-8, MCP-1, and IFN-beta (ELISA)\] induced by LPS and by PAM3CSK4 plus baseline cytokine levels (no exposure to LPS or PAM3CSK4).
Conditions Studied
Study Locations (1)
North Carolina
- NIEHS Clinical Research Unit (CRU) - Research Triangle Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 725 participants |
| Start Date | 2012-07-30 |
What NCT01143480 shows while recruiting
NCT01143480 is an observational study that tracks outcomes without assigning an intervention. The registered 725 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (79% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01143480 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01143480 about?
NCT01143480 is a clinical study titled "Study of the Effect of Innate on the Inflammatory Response to Endotoxin". Background: \- Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s r...
What is the current status of trial NCT01143480?
This trial is currently recruiting. The enrollment target is 725 participants. The study started on 2012-07-30.
What conditions does trial NCT01143480 study?
This clinical trial studies the following conditions: Cancer, Asthma, Insulin Resistance, Metabolic Syndrome, Atherosclerosis.
Who is sponsoring clinical trial NCT01143480?
This trial is sponsored by National Institute of Environmental Health Sciences (NIEHS), which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01143480 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01143480's enrollment target sits among peer trials
725 98th of 615 higher than 518 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT06731478 · 726 participants · Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI